# Bezuclastinib PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/bezuclastinib

> The PDUFA target action date for bezuclastinib, sponsored by Cogent Biosciences, Inc. (COGT), is November 30, 2026. Status: scheduled.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, half-year only, exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### When is the bezuclastinib PDUFA date?

The PDUFA target action date for bezuclastinib, sponsored by Cogent Biosciences, Inc. (COGT), is November 30, 2026. Status: scheduled. Press release filed with the SEC (EX-99): "Preparing for anticipated bezuclastinib launch in GIST; PDUFA action date November 30, 2026" Last confirmed November 5, 2026. [Calendar and source filings](https://sec-api.dev/pdufa/bezuclastinib)

Source: Press release filed with the SEC (EX-99), accession 0001193125-26-449926, https://www.sec.gov/Archives/edgar/data/1622229/000119312526449926/cogt-ex99_1.htm (retrieved 2026-11-12). Last confirmed 2026-11-05. Cite: https://sec-api.dev/pdufa/bezuclastinib#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | bezuclastinib |
| Codes | CGT9486, PLX9486 |
| Sponsor | Cogent Biosciences, Inc. (COGT) https://sec-api.dev/companies/cogt/catalysts |
| Indications | [advsm](https://sec-api.dev/indications/advsm), [nonadvanced systemic mastocytosis](https://sec-api.dev/indications/nonadvanced-systemic-mastocytosis), nonadvsm in december 2025, gist in april 2026, advsm demonstrating clinically meaningful results as measured, non-advanced systemic mastocytosis, Advanced Systemic Mastocytosis (AdvSM), Advanced Gastrointestinal Stromal Tumors |
| Modality | small_molecule |
| FDA designations | breakthrough, orphan, priority review |

## Timeline

### Apr 2023: trial start

- Status: completed. Date confidence: month.
- First seen 2025-08-05, last confirmed 2025-11-07.
- SEC Form 10-Q (accession 0001193125-25-272334): "In April 2023, we initiated Part 2 of the APEX trial, the potentially registrational portion of the study." https://www.sec.gov/Archives/edgar/data/1622229/000119312525272334/cogt-20250930.htm
- SEC Form 10-Q (accession 0000950170-25-102440): "In April 2023, we initiated Part 2 of the APEX trial, the potentially registrational portion of the study." https://www.sec.gov/Archives/edgar/data/1622229/000095017025102440/cogt-20250630.htm

### 2H 2025: topline data readout

- Status: scheduled. Date confidence: half.
- First seen 2025-08-05, last confirmed 2025-08-05.
- Press release filed with the SEC (EX-99) (accession 0000950170-25-102433): "Supported by our recent upsized public offering, Cogent is advancing our mission from a position of strength as we prepare to report top-line results from two additional pivotal trials in GIST and AdvSM in the second half of this year, submit our first New Drug Application by the end of 2025 and make continued progress toward the anticipated commercial launch of bezuclastinib in 2026."" https://www.sec.gov/Archives/edgar/data/1622229/000095017025102433/cogt-ex99_1.htm

### July 7, 2025: topline data readout

- Status: completed, met. Date confidence: exact.
- First seen 2024-11-12, last confirmed 2025-08-05.
- SEC Form 8-K (accession 0001193125-25-155811): "On July 7, 2025, Cogent Biosciences, Inc. (the "Company") announced positive top-line results from the registration-directed Part 2 of the SUMMIT clinical trial of bezuclastinib in patients with non-advanced systemic mastocytosis ("NonAdvSM") demonstrating clinically meaningful and highly statistically significant improvements across the primary and all key secondary endpoints, including patient-reported symptoms and objective measures of mast cell burden." https://www.sec.gov/Archives/edgar/data/1622229/000119312525155811/d156610d8k.htm
- SEC Form 8-K (accession 0001193125-24-273393): "A total of 179 patients were enrolled and top-line results from the trial are expected in July 2025." https://www.sec.gov/Archives/edgar/data/1622229/000119312524273393/d914555d8k.htm
- SEC Form 8-K (accession 0001193125-24-273393): "The Company is actively enrolling patients into APEX Part 2 which is anticipated to complete enrollment in Q1 2025 with top-line results expected in mid-2025." https://www.sec.gov/Archives/edgar/data/1622229/000119312524273393/d914555d8k.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-026103): "APEX trial enrollment in AdvSM patients complete; top-line results expected in 2H 2025" https://www.sec.gov/Archives/edgar/data/1622229/000095017025026103/cogt-ex99_1.htm
- SEC Form 10-Q (accession 0000950170-25-064005): "We expect to report top-line results in July 2025." https://www.sec.gov/Archives/edgar/data/1622229/000095017025064005/cogt-20250331.htm
- SEC Form 10-K (accession 0000950170-25-026115): "We expect to report top-line results in July 2025." https://www.sec.gov/Archives/edgar/data/1622229/000095017025026115/cogt-20241231.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-063987): "Three Registration-Directed Top-line Data Readouts Remain on Track in 2025:" https://www.sec.gov/Archives/edgar/data/1622229/000095017025063987/cogt-ex99_1.htm
- SEC Form 10-Q (accession 0000950170-25-102440): "We completed enrollment in APEX Part 2 in the first quarter of 2025 with 58 patients and expect to present top-line results in the second half of 2025." https://www.sec.gov/Archives/edgar/data/1622229/000095017025102440/cogt-20250630.htm
- SEC Form 10-Q (accession 0000950170-25-064005): "We completed enrollment in APEX Part 2 in the first quarter of 2025 with 58 patients and expect to present top-line results in the second half of 2025." https://www.sec.gov/Archives/edgar/data/1622229/000095017025064005/cogt-20250331.htm
- SEC Form 10-K (accession 0000950170-25-026115): "We completed enrollment in APEX Part 2 in the first quarter of 2025 with 58 patients and expect to present top-line results in the second half of 2025." https://www.sec.gov/Archives/edgar/data/1622229/000095017025026115/cogt-20241231.htm
- SEC Form 10-Q (accession 0000950170-24-124712): "We remain on track to deliver top-line results from the APEX trial by mid-2025." https://www.sec.gov/Archives/edgar/data/1622229/000095017024124712/cogt-20240930.htm

### late 2025: NDA/BLA submission

- Status: scheduled. Date confidence: half.
- First seen 2025-02-25, last confirmed 2025-11-10.
- SEC Form 8-K (accession 0001193125-25-273315): "This Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding: plans to submit an NDA for bezuclastinib in NonAdvSM patients by the end of 2025" https://www.sec.gov/Archives/edgar/data/1622229/000119312525273315/d54064d8k.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-102433): "Supported by our recent upsized public offering, Cogent is advancing our mission from a position of strength as we prepare to report top-line results from two additional pivotal trials in GIST and AdvSM in the second half of this year, submit our first New Drug Application by the end of 2025 and make continued progress toward the anticipated commercial launch of bezuclastinib in 2026."" https://www.sec.gov/Archives/edgar/data/1622229/000095017025102433/cogt-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-102433): "This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding: the company's expectation to report top-line results from both PEAK and APEX in the second half of 2025; the potential for bezuclastinib to become the new standard of care for NonAdvSM patients; the company's expectation to submit its first NDA by the end of 2025; the anticipated commercial launch of bezuclastinib in 2026; and the company's anticipated cash runway into 2027, including through potential FDA approval of bezuclastinib for NonAdvSM and early commercial launch activities." https://www.sec.gov/Archives/edgar/data/1622229/000095017025102433/cogt-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-157390): " Bezuclastinib NDA submission to FDA expected by end of 2025; strong financial position with $237 million current cash balance and access up to an additional $350 million via recently announced debt facility with SLR Capital Partners " https://www.sec.gov/Archives/edgar/data/1622229/000119312525157390/d92808dex991.htm
- SEC Form 8-K (accession 0001193125-25-155811): "Based on these data, the Company is on track to submit its first new drug application ("NDA") to the U.S. Food and Drug Administration ("FDA") for bezuclastinib in NonAdvSM by the end of 2025." https://www.sec.gov/Archives/edgar/data/1622229/000119312525155811/d156610d8k.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-026103): ""Given our strong cash balance, and emerging pipeline of potential best-in-class targeted therapies, we are poised for a transformational year culminating with the planned submission of Cogent's first NDA for bezuclastinib by the end of 2025."" https://www.sec.gov/Archives/edgar/data/1622229/000095017025026103/cogt-ex99_1.htm
- SEC Form 10-Q (accession 0000950170-25-102440): "Based on these data, we plan to submit our first NDA to the FDA for bezuclastinib in NonAdvSM by the end of 2025." https://www.sec.gov/Archives/edgar/data/1622229/000095017025102440/cogt-20250630.htm

### late 2025: trial start

- Status: scheduled. Date confidence: half. Stage: 1.
- First seen 2025-11-03, last confirmed 2025-11-03.
- Press release filed with the SEC (EX-99) (accession 0001193125-25-261797): "and the company's plans to initiate a Phase 1 trial for its ErbB2 program before the end of 2025." https://www.sec.gov/Archives/edgar/data/1622229/000119312525261797/cogt-ex99_1.htm

### September 19, 2025: primary completion

- Status: completed. Date confidence: exact. Stage: 2.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04996875 ((Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2025-09-19 (ACTUAL); Lead Sponsor Cogent Biosciences, Inc.." https://clinicaltrials.gov/study/NCT04996875

### September 30, 2025: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: Advanced Gastrointestinal Stromal Tumors; Metastatic Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05208047 ((Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2025-09-30 (ACTUAL); Lead Sponsor Cogent Biosciences, Inc.." https://clinicaltrials.gov/study/NCT05208047

### Nov 2025: topline data readout

- Status: completed, positive. Date confidence: month. Stage: 3.
- First seen 2026-02-17, last confirmed 2026-11-05.
- Press release filed with the SEC (EX-99) (accession 0001193125-26-053131): "In November 2025, announced topline results from the Phase 3 PEAK trial of bezuclastinib in combination with sunitinib for patients with GIST who have received prior treatment with imatinib, becoming the first positive Phase 3 trial in second-line GIST patients in over 20 years." https://www.sec.gov/Archives/edgar/data/1622229/000119312526053131/cogt-ex99_1.htm
- SEC Form 10-Q (accession 0001193125-26-449963): "We reported top-line results from our PEAK trial in November 2025 and full results in May 2026, which demonstrated a substantial and highly statistically significant clinical benefit on the primary endpoint of progression free survival ("PFS")." https://www.sec.gov/Archives/edgar/data/1622229/000119312526449963/cogt-20260930.htm
- SEC Form 10-Q (accession 0001193125-26-342393): "We reported top-line results from our PEAK trial in November 2025 and full results in May 2026, which demonstrated a substantial and highly statistically significant clinical benefit on the primary endpoint of progression free survival ("PFS")." https://www.sec.gov/Archives/edgar/data/1622229/000119312526342393/cogt-20260630.htm
- SEC Form 10-Q (accession 0001193125-26-205170): "We announced positive top-line results from PEAK in November 2025, which demonstrated a substantial and highly statistically significant clinical benefit on the primary endpoint of progression free survival ("PFS")." https://www.sec.gov/Archives/edgar/data/1622229/000119312526205170/cogt-20260331.htm
- SEC Form 10-K (accession 0001193125-26-053334): "We announced positive top-line results from our PEAK trial in November 2025, which demonstrated a substantial and highly statistically significant clinical benefit on the primary endpoint of PFS." https://www.sec.gov/Archives/edgar/data/1622229/000119312526053334/cogt-20251231.htm
- SEC Form 10-K (accession 0001193125-26-053334): "We announced positive top-line results from PEAK in November 2025, which demonstrated a substantial and highly statistically significant clinical benefit on the primary endpoint of progression free survival ("PFS")." https://www.sec.gov/Archives/edgar/data/1622229/000119312526053334/cogt-20251231.htm

### December 6, 2025: topline data readout

- Status: completed, positive. Date confidence: exact.
- First seen 2025-02-25, last confirmed 2025-12-08.
- SEC Form 8-K (accession 0001193125-25-311217): "On December 6, 2025 and December 8, 2025, Cogent Biosciences, Inc. (the "Company") presented the full results from its SUMMIT clinical trial of bezuclastinib in patients with nonadvanced systemic mastocytosis ("NonAdvSM") and announced positive top-line results from its APEX clinical trial of bezuclastinib in patients with advanced systemic mastocytosis ("AdvSM"), respectively." https://www.sec.gov/Archives/edgar/data/1622229/000119312525311217/d81277d8k.htm
- SEC Form 8-K (accession 0001193125-25-311217): "On December 8, 2025, the Company announced positive top-line results from the registration-directed APEX Part 2 clinical trial of bezuclastinib in patients with AdvSM demonstrating clinically meaningful results as measured by consensus criteria used to assess patient response." https://www.sec.gov/Archives/edgar/data/1622229/000119312525311217/d81277d8k.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-261797): "This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding: plans to present top-line results from the company's PEAK trial in November 2025" https://www.sec.gov/Archives/edgar/data/1622229/000119312525261797/cogt-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-026103): "Top-line results from PEAK trial in 2nd-line GIST patients expected by end of 2025" https://www.sec.gov/Archives/edgar/data/1622229/000095017025026103/cogt-ex99_1.htm
- SEC Form 8-K (accession 0001193125-25-273315): "plans to announce top-line results from the APEX trial in December 2025" https://www.sec.gov/Archives/edgar/data/1622229/000119312525273315/d54064d8k.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-261797): "plans to present top-line results from the company's APEX trial in December 2025" https://www.sec.gov/Archives/edgar/data/1622229/000119312525261797/cogt-ex99_1.htm
- SEC Form 10-Q (accession 0001193125-25-272334): "We completed enrollment in APEX Part 2 in the first quarter of 2025 with 58 patients and plan to present top-line results in December 2025." https://www.sec.gov/Archives/edgar/data/1622229/000119312525272334/cogt-20250930.htm

### Jan 2026: NDA/BLA acceptance

- Status: completed. Date confidence: month. Indication: NonAdvSM in December 2025.
- First seen 2026-02-17, last confirmed 2026-11-05.
- SEC prospectus (424B) (accession 0001193125-26-342683): "We submitted our first NDA for bezuclastinib in patients with NonAdvSM in December 2025, which was accepted by the FDA in March 2026 and assigned a Prescription Drug User Fee Act ("PDUFA") target action date of December 30, 2026." https://www.sec.gov/Archives/edgar/data/1622229/000119312526342683/d149476d424b5.htm
- SEC Form 10-Q (accession 0001193125-26-449963): "In January 2026, we announced that the FDA agreed to accept our NDA for bezuclastinib in combination with sunitinib for patients with GIST who have received prior treatment with imatinib under the Real-Time Oncology Review ("RTOR") program and we submitted our GIST NDA in March 2026 under this program, which was accepted by the FDA with Priority Review in May 2026." https://www.sec.gov/Archives/edgar/data/1622229/000119312526449963/cogt-20260930.htm
- SEC Form 10-Q (accession 0001193125-26-342393): "In January 2026, we announced that the FDA agreed to accept our NDA for bezuclastinib in combination with sunitinib for patients with GIST who have received prior treatment with imatinib under the Real-Time Oncology Review ("RTOR") program and we submitted our GIST NDA in March 2026 under this program, which was accepted by the FDA with Priority Review in May 2026." https://www.sec.gov/Archives/edgar/data/1622229/000119312526342393/cogt-20260630.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-053131): "the expectation for FDA to accept the company's NDA for bezuclastinib in NonAdvSM in February 2026" https://www.sec.gov/Archives/edgar/data/1622229/000119312526053131/cogt-ex99_1.htm

### Jan 2026: NDA/BLA submission

- Status: completed. Date confidence: month.
- First seen 2026-02-17, last confirmed 2026-02-17.
- SEC Form 10-K (accession 0001193125-26-053334): "We submitted the first New Drug Application ("NDA") for NonAdvSM in 2025; we initiated our NDA submission for GIST in January 2026 and expect to complete the submission in April 2026; and we plan to submit an NDA in AdvSM in the first half of 2026." https://www.sec.gov/Archives/edgar/data/1622229/000119312526053334/cogt-20251231.htm

### Apr 2026: NDA/BLA submission

- Status: scheduled. Date confidence: month. Indication: AdvSM.
- First seen 2025-11-10, last confirmed 2026-05-05.
- Press release filed with the SEC (EX-99) (accession 0001193125-26-053131): "plans to complete the submission of an NDA for bezuclastinib in combination with sunitinib in patients with GIST in April 2026" https://www.sec.gov/Archives/edgar/data/1622229/000119312526053131/cogt-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-205124): "the expectation to submit an NDA for bezuclastinib in patients with AdvSM in the first half of 2026" https://www.sec.gov/Archives/edgar/data/1622229/000119312526205124/cogt-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-053131): "This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding: plans to submit an NDA for bezuclastinib in patients with AdvSM in the first half of 2026" https://www.sec.gov/Archives/edgar/data/1622229/000119312526053131/cogt-ex99_1.htm
- SEC Form 8-K (accession 0001193125-25-311217): "Based on these top-line data, Cogent expects to submit a new drug application ("NDA") to the U.S. Food and Drug Administration ("FDA") for bezuclastinib in AdvSM during the first half of 2026." https://www.sec.gov/Archives/edgar/data/1622229/000119312525311217/d81277d8k.htm
- SEC Form 8-K (accession 0001193125-25-311217): "This Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding: plans to submit an NDA to the FDA for bezuclastinib in AdvSM during the first half of 2026 and plans to present detailed results from the APEX trial at an upcoming scientific meeting in the first half of 2026." https://www.sec.gov/Archives/edgar/data/1622229/000119312525311217/d81277d8k.htm
- SEC Form 8-K (accession 0001193125-25-273315): "plans to submit an NDA for bezuclastinib in imatinib-resistant GIST patients in the first half of 2026" https://www.sec.gov/Archives/edgar/data/1622229/000119312525273315/d54064d8k.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-273315): "NDA submission for bezuclastinib in imatinib-resistant or intolerant GIST planned 1H 2026 based on results of the Peak trial 17" https://www.sec.gov/Archives/edgar/data/1622229/000119312525273315/d54064dex991.htm

### mid-2026: trial start

- Status: scheduled. Date confidence: half. Stage: 2.
- First seen 2026-02-17, last confirmed 2026-05-05.
- SEC Form 10-Q (accession 0001193125-26-205170): "In mid-2026, we expect to initiate a Phase 2 trial investigating the benefit of the bezuclastinib plus sunitinib combination for first-line GIST patients with exon 9 mutations who are naive to, or recently initiated treatment with, imatinib." https://www.sec.gov/Archives/edgar/data/1622229/000119312526205170/cogt-20260331.htm
- SEC Form 10-K (accession 0001193125-26-053334): "In mid-2026, we expect to initiate a Phase 2 trial investigating the benefit of the bezuclastinib combination for first-line GIST patients with exon 9 mutations who are naive to, or recently initiated treatment with, imatinib." https://www.sec.gov/Archives/edgar/data/1622229/000119312526053334/cogt-20251231.htm
- SEC Form 10-K (accession 0001193125-26-053334): "In mid-2026, we expect to initiate a Phase 2 trial investigating the benefit of the bezuclastinib plus sunitinib combination for first-line GIST patients with exon 9 mutations who are naive to, or recently initiated treatment with, imatinib." https://www.sec.gov/Archives/edgar/data/1622229/000119312526053334/cogt-20251231.htm

### May 5, 2026: NDA/BLA acceptance

- Status: completed. Date confidence: exact. Indication: NonAdvanced Systemic Mastocytosis.
- First seen 2026-05-05, last confirmed 2026-05-05.
- Press release filed with the SEC (EX-99) (accession 0001193125-26-205124): "Announced the FDA accepted its NDA for bezuclastinib in patients with NonAdvanced Systemic Mastocytosis (NonAdvSM) and assigned a Prescription Drug User Fee Act (PDUFA) target action date of December 30, 2026" https://www.sec.gov/Archives/edgar/data/1622229/000119312526205124/cogt-ex99_1.htm

### Jun 2026: NDA/BLA submission

- Status: completed. Date confidence: month. Indication: AdvSM.
- First seen 2026-08-10, last confirmed 2026-08-10.
- SEC prospectus (424B) (accession 0001193125-26-342683): "In June 2026, we submitted our third NDA for bezuclastinib in patients with AdvSM." https://www.sec.gov/Archives/edgar/data/1622229/000119312526342683/d149476d424b5.htm

### August 10, 2026: NDA/BLA acceptance

- Status: completed. Date confidence: exact.
- First seen 2026-08-10, last confirmed 2026-08-10.
- Press release filed with the SEC (EX-99) (accession 0001193125-26-341315): "Announced FDA acceptance of the New Drug Application (NDA) with priority review for bezuclastinib in combination with sunitinib in patients with GIST who have received prior treatment with imatinib." https://www.sec.gov/Archives/edgar/data/1622229/000119312526341315/cogt-ex99_1.htm

### November 5, 2026: NDA/BLA acceptance

- Status: completed. Date confidence: exact.
- First seen 2026-11-05, last confirmed 2026-11-05.
- Press release filed with the SEC (EX-99) (accession 0001193125-26-449926): "Announced the U.S. Food and Drug Administration (FDA) acceptance of the New Drug Application (NDA) for bezuclastinib in Advanced Systemic Mastocytosis (AdvSM)." https://www.sec.gov/Archives/edgar/data/1622229/000119312526449926/cogt-ex99_1.htm

### November 30, 2026: PDUFA date

- Status: scheduled. Date confidence: exact.
- First seen 2026-08-10, last confirmed 2026-11-05.
- Press release filed with the SEC (EX-99) (accession 0001193125-26-449926): "Preparing for anticipated bezuclastinib launch in GIST; PDUFA action date November 30, 2026" https://www.sec.gov/Archives/edgar/data/1622229/000119312526449926/cogt-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-449926): "Potential FDA approval of bezuclastinib in GIST - PDUFA date of November 30, 2026" https://www.sec.gov/Archives/edgar/data/1622229/000119312526449926/cogt-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-341315): "Potential FDA approval of bezuclastinib in GIST - PDUFA date of November 30, 2026" https://www.sec.gov/Archives/edgar/data/1622229/000119312526341315/cogt-ex99_1.htm
- SEC prospectus (424B) (accession 0001193125-26-342683): "In March 2026, we submitted our second NDA for bezuclastinib in combination with sunitinib for patients with GIST who have received prior treatment with imatinib under the FDA's Real-Time Oncology Review program, which the FDA accepted with Priority Review and assigned a PDUFA target action date of November 30, 2026." https://www.sec.gov/Archives/edgar/data/1622229/000119312526342683/d149476d424b5.htm
- SEC Form 10-Q (accession 0001193125-26-449963): "The FDA assigned a PDUFA target action date of November 30, 2026." https://www.sec.gov/Archives/edgar/data/1622229/000119312526449963/cogt-20260930.htm
- SEC Form 10-Q (accession 0001193125-26-342393): "The FDA assigned a PDUFA target action date of November 30, 2026." https://www.sec.gov/Archives/edgar/data/1622229/000119312526342393/cogt-20260630.htm

### December 30, 2026: PDUFA date

- Status: scheduled. Date confidence: exact. Indication: NonAdvanced Systemic Mastocytosis.
- First seen 2026-05-05, last confirmed 2026-11-05.
- Press release filed with the SEC (EX-99) (accession 0001193125-26-449926): "Potential FDA approval of bezuclastinib in NonAdvSM - PDUFA date of December 30, 2026" https://www.sec.gov/Archives/edgar/data/1622229/000119312526449926/cogt-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-341315): "Potential FDA approval of bezuclastinib in NonAdvSM - PDUFA date of December 30, 2026" https://www.sec.gov/Archives/edgar/data/1622229/000119312526341315/cogt-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-205124): "Announced the FDA accepted its NDA for bezuclastinib in patients with NonAdvanced Systemic Mastocytosis (NonAdvSM) and assigned a Prescription Drug User Fee Act (PDUFA) target action date of December 30, 2026" https://www.sec.gov/Archives/edgar/data/1622229/000119312526205124/cogt-ex99_1.htm
- SEC prospectus (424B) (accession 0001193125-26-342683): "We submitted our first NDA for bezuclastinib in patients with NonAdvSM in December 2025, which was accepted by the FDA in March 2026 and assigned a Prescription Drug User Fee Act ("PDUFA") target action date of December 30, 2026." https://www.sec.gov/Archives/edgar/data/1622229/000119312526342683/d149476d424b5.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-449926): "NonAdvSM PDUFA target action date December 30, 2026; AdvSM PDUFA target action date" https://www.sec.gov/Archives/edgar/data/1622229/000119312526449926/cogt-ex99_1.htm
- SEC Form 10-Q (accession 0001193125-26-449963): "The FDA assigned a Prescription Drug User Fee Act ("PDUFA") target action date of December 30, 2026." https://www.sec.gov/Archives/edgar/data/1622229/000119312526449963/cogt-20260930.htm
- SEC Form 10-Q (accession 0001193125-26-342393): "The FDA assigned a Prescription Drug User Fee Act ("PDUFA") target action date of December 30, 2026." https://www.sec.gov/Archives/edgar/data/1622229/000119312526342393/cogt-20260630.htm
- SEC Form 10-Q (accession 0001193125-26-205170): "The FDA assigned a Prescription Drug User Fee Act ("PDUFA") target action date of December 30, 2026." https://www.sec.gov/Archives/edgar/data/1622229/000119312526205170/cogt-20260331.htm

### June 29, 2027: PDUFA date

- Status: scheduled. Date confidence: exact.
- First seen 2026-11-05, last confirmed 2026-11-05.
- Press release filed with the SEC (EX-99) (accession 0001193125-26-449926): "Potential FDA approval of bezuclastinib in AdvSM - PDUFA date of June 29, 2027" https://www.sec.gov/Archives/edgar/data/1622229/000119312526449926/cogt-ex99_1.htm
- SEC Form 10-Q (accession 0001193125-26-449963): "The FDA assigned a PDUFA target action date of June 29, 2027." https://www.sec.gov/Archives/edgar/data/1622229/000119312526449963/cogt-20260930.htm

### late 2028: PDUFA date

- Status: scheduled. Date confidence: half.
- First seen 2026-11-05, last confirmed 2026-11-05.
- Press release filed with the SEC (EX-99) (accession 0001193125-26-449926): "The company believes that its cash, cash equivalents and marketable securities will be sufficient to fund its operating expenses and capital expenditure requirements into late 2028, well past all three pending PDUFA action dates for bezuclastinib." https://www.sec.gov/Archives/edgar/data/1622229/000119312526449926/cogt-ex99_1.htm
- SEC Form 10-Q (accession 0001193125-26-449963): "We believe that our cash, cash equivalents and marketable securities will be sufficient to fund our operating expenses and capital expenditure requirements into late 2028, well past all three pending PDUFA action dates for bezuclastinib." https://www.sec.gov/Archives/edgar/data/1622229/000119312526449963/cogt-20260930.htm
- SEC Form 10-Q (accession 0001193125-26-449963): "We believe that our cash, cash equivalents and marketable securities will be sufficient to fund our operating expenses and capital expenditure requirements into late 2028, well past all three pending PDUFA action dates or bezuclastinib." https://www.sec.gov/Archives/edgar/data/1622229/000119312526449963/cogt-20260930.htm

Calendar months: [November 2026](https://sec-api.dev/fda-calendar/2026-11), [December 2026](https://sec-api.dev/fda-calendar/2026-12), [June 2027](https://sec-api.dev/fda-calendar/2027-06)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/bezuclastinib.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Bezuclastinib PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/bezuclastinib

```bibtex
@misc{secapidev_pdufa_bezuclastinib_20261116,
  title        = {Bezuclastinib PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/bezuclastinib}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_bezuclastinib_20261116","title":"Bezuclastinib PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/bezuclastinib","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
